论文部分内容阅读
目的:观察雷贝拉唑联合胃康胶囊治疗胃炎的临床效果。方法:110例胃炎患者随机分为2组。对照组给予雷贝拉唑钠肠溶片20 mg,po,qd,研究组在对照组基础上加用胃康胶囊1.2 g,po,tid。两组均治疗7 d。比较两组患者的临床疗效、药品不良反应,以及住院时间和症状消失时间。结果:研究组总有效率为90.9%,明显高于对照组的67.3%(P<0.05);研究组患者的症状消失时间及住院时间均明显短于对照组(P<0.05)。研究组药品不良反应发生率明显低于对照组(P<0.05)。结论:雷贝拉唑联合胃康胶囊治疗胃炎的临床效果明显优于单用雷贝拉唑,可迅速改善患者临床症状,且不良反应较少,值得临床推广使用。
Objective: To observe the clinical effect of rabeprazole and Weikang capsule in the treatment of gastritis. Methods: 110 cases of gastritis were randomly divided into two groups. Control group was given rabeprazole sodium enteric-coated tablets 20 mg, po, qd, the study group in the control group based on the use of Weikang capsule 1.2 g, po, tid. Both groups were treated for 7 days. The clinical efficacy, drug adverse reactions, and length of hospitalization and symptom disappearance in both groups were compared. Results: The total effective rate was 90.9% in the study group, which was significantly higher than 67.3% in the control group (P <0.05). The symptom disappearance time and hospitalization time in the study group were significantly shorter than those in the control group (P <0.05). The incidence of adverse drug reactions in the study group was significantly lower than that in the control group (P <0.05). Conclusion: The rabeprazole combined with Weikang capsule is superior to rabeprazole alone in the treatment of gastritis, which can rapidly improve the clinical symptoms of patients with less adverse reactions and is worthy of clinical promotion.